Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

CLARISCAN SOLUTION FOR INJECTION IN VIAL 0.5 MMOL/ML [SIN15693P]

Active ingredients: CLARISCAN SOLUTION FOR INJECTION IN VIAL 0.5 MMOL/ML

View product's general information
Last updated 24 April 2026

Product Info

CLARISCAN SOLUTION FOR INJECTION IN VIAL 0.5 MMOL/ML

[SIN15693P]

Product information

Active Ingredient and Strength

GADOTERATE MEGLUMINE 376.9 MG/ML EQV GADOTERIC ACID - 279.32 MG/ML

Dosage Form

INJECTION, SOLUTION

Manufacturer and Country

GE HEALTHCARE AS (OSLO SITE) - NORWAY

Registration Number

SIN15693P

Licence Holder

GE HEALTHCARE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

V08CA02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Indications

This medicinal product is for diagnostic use only.

Clariscan is a contrast agent indicated for enhancement of the contrast in Magnetic Resonance Imaging for a better visualization/delineation.

  • Neuroradiology: tumour of the spine and the surrounding tissues, intracranial tumours.

  • Abdominal radiology: primary and secondary tumours.

  • Primary tumour of the bone and soft tissues.

Clariscan should be used only when diagnostic information is essential and not available with unenhanced magnetic resonance imaging (MRI).

Dosing

4.2 Posology and method of administration

This medicinal product should only be administered by trained healthcare professionals with technical expertise in performing and interpreting gadolinium enhanced MRI.

Posology

Adults including the elderly:
The recommended dose is 0.1 mmol/kg, i.e. 0.2 mL/kg which is sufficient to provide diagnostically adequate contrast.

Children (aged 2 years and above):
The adult dose applies to these patients.

The lowest dose that provides sufficient enhancement for diagnostic purposes should be used. The dose should be calculated based on the patient’s body weight, and should not exceed the recommended dose per kilogram of body weight detailed in this section.

Whole body MRI (including lesions of the liver, kidneys, pancreas, pelvis, lungs, heart, breast, and musculoskeletal system)
The recommended dose is 0.1 mmol/kg BW, i.e. 0.2 mL/kg BW to provide diagnostically adequate contrast.

Special populations

Impaired renal function
The adult dose applies to patients with mild to moderate renal impairment (GFR ≥ 30 ml/min/1.73m2).

Clariscan should only be used in patients with severe renal impairment (GFR < 30 mL /min/1.73m2) and in patients in the perioperative liver transplantation period after careful risk/benefit assessment and if the diagnostic information is essential and not available with non-contrast enhanced MRI (see 4.4 Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). If it is necessary to use Clariscan the dose should not exceed 0.1 mmol/kg body weight.

More than one dose should not be used during a scan. Because of the lack of information on repeated administration, Clariscan injections should not be repeated unless the interval between injections is at least 7 days.

Impaired hepatic function
The adult dose applies to these patients. Caution is recommended, especially in the case of perioperative liver transplantation period (see above impaired renal function).

Elderly (aged 65 years and above)
No dosage adjustment is considered necessary. Caution should be exercised in elderly patients (see 4.4 Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Paediatric population (aged 2–18 years)
Encephalic and Spinal MRI, Whole body MRI:
The recommended and maximum dose of Clariscan is 0.1 mmol/kg body weight. More than one dose should not be used during a scan.

Method of administration

The product is indicated for intravenous administration only.
Infusion rate: 3–5 mL/min (higher infusion rates up to 120 mL/min, i.e. 2 mL/sec, may be used for angiographic procedures). For instructions on preparation and disposal, see 6.6 Instructions for use/handling – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Intravascular administration of contrast media should, if possible, be done with the patient lying down. After the administration, the patient should be kept under observation for at least half an hour, since experience shows that the majority of undesirable effects occur within this time.

For single patient use only, any unused solution should be discarded.

Paediatric population (2–18 years). Depending on the amount of Clariscan to be given to the child, it is preferable to use Clariscan vials with a single use syringe of a volume adapted to this amount in order to have a better precision of the injected volume.

In neonates and infants the required dose should be administered by hand.

Image acquisition
Contrast enhanced MRI may be initiated immediately after administration of the agent. Optimal imaging: within 45 minutes after injection. Optimal image sequence: T1-weighted

Contraindications

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in 6.1 List of Excipients – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.